Valuation dashboard for Abeona Therapeutics Inc. (ABEO) with P/E N/A, P/B 2.39, EV/EBITDA -3.81 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa.
Analysis Summary
Abeona Therapeutics Inc. reported revenue of $5.8M in the most recent fiscal year, growing at a 5-year CAGR of -10.3%.
Trailing-twelve-month margins: gross margin 56.6%, operating margin -327.6%, net margin -246.4%.
At the current price of $5.37, ABEO has negative trailing earnings (P/E not meaningful) and an ROE of -41.69%. Market capitalisation stands at $306M.
Balance sheet quality for ABEO: current ratio of 6.9. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 2.39 |
| EV / EBITDA | -3.81 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $1.00 |
| vs Current Price | -81.4% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ABEO | Abeona Therapeutics Inc. | $306M | 2.39 | -41.7% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $5.37 |
| Market Cap | $306M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -41.69% |
| Return on Invested Capital | -39.66% |
| Return on Assets | -35.03% |
| Gross Margin | 56.63% |
| Operating Margin | -327.64% |
| Net Margin | -246.42% |
Related companies: ARCT · ASMB · ELDN · FHTX · HUMA · PBYI · SGMT
Explore sector: Healthcare · Biotechnology
More sections of ABEO: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks